Study guide
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State
Key Takeaways Explain This Topic AI
Volume of distribution ( V d = Dose C 0 V_d = \frac{\text{Dose}}{C_0} V d = C 0 Dose ) is an apparent proportionality volume linking total drug in the body to plasma concentration; highly protein-bound or hydrophilic drugs exhibit low V d V_d V d (warfarin about 0.14 L/kg 0.14\text{ L/kg} 0.14 L/kg ; aminoglycosides about 0.25 L/kg 0.25\text{ L/kg} 0.25 L/kg ), whereas lipophilic drugs with high tissue binding exhibit very high V d V_d V d ( > 1 – 5 L/kg > 1\text{--}5\text{ L/kg} > 1 – 5 L/kg , e.g., digoxin, chloroquine, amiodarone).
Elimination kinetics dictate drug clearance: first-order elimination clears a constant fraction of drug per unit time ( k e = 0.693 t 1 / 2 k_e = \frac{0.693}{t_{1/2}} k e = t 1/2 0.693 ) with plasma concentration decaying exponentially, whereas zero-order elimination clears a constant absolute amount per unit time due to enzyme saturation at therapeutic concentrations (e.g., phenytoin, ethanol, high-dose salicylates).
Systemic clearance ( C L = k e × V d = F × Dose AUC CL = k_e \times V_d = \frac{F \times \text{Dose}}{\text{AUC}} C L = k e × V d = AUC F × Dose ) represents the volume of biological fluid cleared of active drug per unit time and is the primary determinant of the maintenance dose ( M D = C L × C target × τ F MD = \frac{CL \times C_{\text{target}} \times \tau}{F} M D = F C L × C target × τ ).
Loading dose ( L D = V d × C target F LD = \frac{V_d \times C_{\text{target}}}{F} L D = F V d × C target ) depends solely on V d V_d V d and target peak concentration to rapidly achieve therapeutic levels in acute emergencies, completely independent of drug clearance or elimination rate.
In first-order kinetics, reaching steady state ( C ss C_{\text{ss}} C ss ) requires 4 to 5 4\text{ to }5 4 to 5 elimination half-lives ( 93.75 % – 96.88 % 93.75\%\text{--}96.88\% 93.75% – 96.88% of plateau), and similarly, drug elimination after therapy discontinuation requires 4 to 5 4\text{ to }5 4 to 5 half-lives for near-total clearance.
Last updated: October 2026
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State
Clinical pharmacokinetics describes the quantitative relationship between drug dose, biological drug concentrations in body fluids, and the time course of pharmacological response and toxicity. The fate of any xenobiotic administered to a patient is governed by the foundational ADME cascade: Absorption , Distribution , Metabolism , and Excretion . While pharmacodynamics explores what a drug does to the body, pharmacokinetics quantifies what the body does to the drug.
Mastery of core pharmacokinetic equations enables pharmacists to individualize drug regimens, anticipate toxic accumulations in organ failure, calculate initial loading doses, and adjust maintenance therapy to achieve optimal patient outcomes. On Canadian pharmacist licensing examinations, candidates are expected to understand the physiological basis of these parameters and accurately execute pharmacokinetic calculations.
Apparent Volume of Distribution ( V d V_d V d )
The apparent volume of distribution ( V d V_d V d ) is a proportionality constant that relates the total amount of drug present in the body to the measured concentration of drug in plasma or serum at that specific point in time:
V d = Amount of Drug in Body C p V_d = \frac{\text{Amount of Drug in Body}}{C_p} V d = C p Amount of Drug in Body
Following a rapid single intravenous (IV) bolus injection, assuming instantaneous distribution throughout a single-compartment model, V d V_d V d is calculated by extrapolating the initial plasma concentration back to time zero ( C 0 C_0 C 0 ):
- V d = Dose IV C 0 V_d = \frac{\text{Dose}_{\text{IV}}}{C_0} V d = C 0 Dose IV
- Physiological Meaning and Fluid Compartments
V d V_d V d is termed an "apparent" volume because it does not represent an actual physical or anatomical fluid space. Instead, it reflects the hypothetical volume of fluid into which the drug would have to be uniformly dissolved to achieve the concentration observed in plasma. In an average 70 kg 70\text{ kg} 70 kg adult, physiological body water is distributed into three main compartments:
Plasma Volume : ≈ 3 L \approx 3\text{ L} ≈ 3 L ( 0.04 – 0.05 L/kg 0.04\text{--}0.05\text{ L/kg} 0.04 – 0.05 L/kg )
Extracellular Fluid (ECF) (Plasma + Interstitial Fluid): ≈ 14 L \approx 14\text{ L} ≈ 14 L ( 0.2 – 0.25 L/kg 0.2\text{--}0.25\text{ L/kg} 0.2 – 0.25 L/kg )
Total Body Water (TBW) (ECF + Intracellular Fluid): ≈ 42 L \approx 42\text{ L} ≈ 42 L ( 0.6 L/kg 0.6\text{ L/kg} 0.6 L/kg )
Distribution Pattern Apparent V d V_d V d Range Physicochemical & Biological Characteristics Representative Drug Examples
Vascular Restriction Low ( < 0.1 – 0.2 L/kg < 0.1\text{--}0.2\text{ L/kg} < 0.1 – 0.2 L/kg ) Highly polar/hydrophilic, large molecular weight, or extensively bound to plasma albumin ( > 90 % >90\% > 90% ) Heparin ( V d ≈ 0.06 L/kg V_d \approx 0.06\text{ L/kg} V d ≈ 0.06 L/kg ), Warfarin ( V d ≈ 0.14 L/kg V_d \approx 0.14\text{ L/kg} V d ≈ 0.14 L/kg )
Extracellular Distribution Intermediate ( 0.2 – 0.4 L/kg 0.2\text{--}0.4\text{ L/kg} 0.2 – 0.4 L/kg ) Moderately hydrophilic, small molecules distributed into interstitial spaces, poor lipid membrane penetration Aminoglycosides (Gentamicin/Tobramycin, V d ≈ 0.25 L/kg V_d \approx 0.25\text{ L/kg} V d ≈ 0.25 L/kg ), Beta-lactams
Extensive Tissue Uptake High ( > 1.0 L/kg > 1.0\text{ L/kg} > 1.0 L/kg , often > 5 L/kg > 5\text{ L/kg} > 5 L/kg ) Highly lipophilic, extensive binding to intracellular proteins, adipose tissue, or deep tissue receptors Digoxin ( V d ≈ 7 L/kg V_d \approx 7\text{ L/kg} V d ≈ 7 L/kg ), Amiodarone ( V d ≈ 60 L/kg V_d \approx 60\text{ L/kg} V d ≈ 60 L/kg ), Chloroquine ( V d > 100 L/kg V_d > 100\text{ L/kg} V d > 100 L/kg )
Note
A drug with a V d V_d V d of 500 L 500\text{ L} 500 L in a 70 kg 70\text{ kg} 70 kg human does not mean the patient contains 500 L 500\text{ L} 500 L of fluid. It signifies that the drug is avidly sequestered inside peripheral tissue cells (e.g., cardiac myocytes, skeletal muscle, or adipose depots), leaving only a minute fraction in circulating plasma.
The Free Drug Hypothesis and Protein Binding
Only free (unbound) drug ( C u C_u C u ) is therapeutically active, able to diffuse across capillary endothelial membranes, interact with pharmacological receptors, and undergo hepatic metabolism or glomerular filtration:
C u = f u × C total C_u = f_u \times C_{\text{total}} C u = f u × C total
Where f u f_u f u is the fraction unbound. Drugs bind primarily to two circulating plasma proteins:
Albumin : Binds predominantly acidic drugs (e.g., phenytoin, warfarin, salicylates, valproic acid, methotrexate).
Alpha-1-Acid Glycoprotein (AAG) : Binds predominantly basic drugs (e.g., lidocaine, propranolol, quinidine, tricyclic antidepressants). AAG is an acute-phase reactant whose plasma concentration surges during acute inflammation, trauma, surgery, or malignancy.
When a drug is highly protein-bound ( > 90 % >90\% > 90% , such as phenytoin or warfarin), pathological states that reduce albumin synthesis (cirrhosis, nephrotic syndrome, malnutrition, severe burns, critical illness) expand the unbound fraction ( f u f_u f u ). This may cause drug toxicity even when the measured total plasma drug concentration appears within the normal reference range.
Systemic Clearance ( C L CL C L ) and Area Under the Curve (AUC)
Systemic clearance ( C L CL C L ) is the volume of biological fluid (blood or plasma) completely cleared of active drug per unit time. Its standard units are mL/min \text{mL/min} mL/min or L/hr \text{L/hr} L/hr . Clearance is an additive parameter reflecting the sum of all individual organ clearance mechanisms:
C L systemic = C L renal + C L hepatic + C L biliary + C L pulmonary + C L other CL_{\text{systemic}} = CL_{\text{renal}} + CL_{\text{hepatic}} + CL_{\text{biliary}} + CL_{\text{pulmonary}} + CL_{\text{other}} C L systemic = C L renal + C L hepatic + C L biliary + C L pulmonary + C L other
Clearance is mathematically defined as the rate of drug elimination divided by the plasma drug concentration:
C L = Rate of Elimination C p = d E / d t C p CL = \frac{\text{Rate of Elimination}}{C_p} = \frac{dE/dt}{C_p} C L = C p Rate of Elimination = C p d E / d t
Model-Independent Clearance & Bioavailability ( F F F )
Following single-dose administration, total systemic clearance is calculated without assuming a specific compartmental model using the Area Under the Plasma Concentration-Time Curve (AUC) :
C L = F × Dose AUC 0 ∞ CL = \frac{F \times \text{Dose}}{\text{AUC}_0^\infty} C L = AUC 0 ∞ F × Dose
Where F F F is the absolute bioavailability —the fraction of administered drug that reaches systemic circulation unchanged. For an intravenous dose, F = 1.0 F = 1.0 F = 1.0 ( 100 % 100\% 100% ). For extravascular routes (oral, subcutaneous, intramuscular), F F F is determined by comparing oral and IV AUC values adjusted for dose:
F = AUC oral × Dose IV AUC IV × Dose oral F = \frac{\text{AUC}_{\text{oral}} \times \text{Dose}_{\text{IV}}}{\text{AUC}_{\text{IV}} \times \text{Dose}_{\text{oral}}} F = AUC IV × Dose oral AUC oral × Dose IV
Hepatic Clearance and Extraction Ratio ( E H E_H E H )
Hepatic clearance ( C L H CL_H C L H ) is the product of hepatic blood flow ( Q H ≈ 1.5 L/min Q_H \approx 1.5\text{ L/min} Q H ≈ 1.5 L/min or 90 L/hr 90\text{ L/hr} 90 L/hr ) and the hepatic extraction ratio ( E H E_H E H ):
C L H = Q H × E H = Q H × ( C in − C out C in ) CL_H = Q_H \times E_H = Q_H \times \left(\frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}}\right) C L H = Q H × E H = Q H × ( C in C in − C out )
Drugs are categorized based on their extraction ratio:
High-Extraction Drugs ( E H > 0.7 E_H > 0.7 E H > 0.7 ) : (e.g., morphine, lidocaine, propranolol, verapamil, nitroglycerin). Clearance is perfusion-limited (dependent on liver blood flow Q H Q_H Q H ). Oral bioavailability is low ( F ≈ 1 − E H < 30 % F \approx 1 - E_H < 30\% F ≈ 1 − E H < 30% ) due to massive first-pass hepatic metabolism. Factors reducing cardiac output or hepatic blood flow (e.g., severe heart failure, beta-blockers, portosystemic shunting) drastically impair clearance.
Low-Extraction Drugs ( E H < 0.3 E_H < 0.3 E H < 0.3 ) : (e.g., warfarin, phenytoin, theophylline, diazepam). Clearance is capacity-limited (dependent on intrinsic microsomal enzyme activity C L int CL_{\text{int}} C L int and unbound fraction f u f_u f u ). Oral bioavailability is high ( F > 70 % F > 70\% F > 70% ), and clearance is insensitive to changes in liver blood flow, but highly sensitive to enzyme induction, enzyme inhibition, and protein binding displacement.
Elimination Rate Constant ( k e k_e k e ) and Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 )
The elimination rate constant ( k e k_e k e ) represents the fractional rate at which drug is removed from the body per unit time (standard units: hr − 1 \text{hr}^{-1} hr − 1 or min − 1 \text{min}^{-1} min − 1 ):
k e = C L V d k_e = \frac{CL}{V_d} k e = V d C L
Under first-order linear kinetics, the plasma drug concentration declines exponentially according to the integrated first-order decay equation:
C t = C 0 × e − k e t C_t = C_0 \times e^{-k_e t} C t = C 0 × e − k e t ln ( C t ) = ln ( C 0 ) − k e t \ln(C_t) = \ln(C_0) - k_e t ln ( C t ) = ln ( C 0 ) − k e t
Taking the natural logarithm of both sides demonstrates that a plot of ln ( C p ) \ln(C_p) ln ( C p ) versus time yields a straight line with a slope equal to − k e -k_e − k e . If two plasma concentrations ( C 1 C_1 C 1 at time t 1 t_1 t 1 , and C 2 C_2 C 2 at time t 2 t_2 t 2 ) are measured:
k e = ln ( C 1 ) − ln ( C 2 ) t 2 − t 1 k_e = \frac{\ln(C_1) - \ln(C_2)}{t_2 - t_1} k e = t 2 − t 1 l n ( C 1 ) − l n ( C 2 )
Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 )
The elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) is the time required for the plasma drug concentration to decrease by exactly 50 % 50\% 50% :
t 1 / 2 = ln ( 2 ) k e = 0.693 k e t_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693}{k_e} t 1/2 = k e l n ( 2 ) = k e 0.693
Substituting k e = C L V d k_e = \frac{CL}{V_d} k e = V d C L yields the fundamental relationship:
t 1 / 2 = 0.693 × V d C L t_{1/2} = \frac{0.693 \times V_d}{CL} t 1/2 = C L 0.693 × V d
Important
Elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) is a secondary / hybrid parameter determined by two primary physiological variables: volume of distribution ( V d V_d V d ) and clearance ( C L CL C L ).
If clearance ( C L CL C L ) decreases (e.g., declining renal function), t 1 / 2 t_{1/2} t 1/2 prolongs .
If volume of distribution ( V d V_d V d ) expands (e.g., aggressive fluid resuscitation in septic shock, massive ascites, or congestive heart failure), t 1 / 2 t_{1/2} t 1/2 prolongs , even if organ clearance remains completely normal!
First-Order Kinetics vs. Zero-Order / Non-Linear (Michaelis-Menten) Kinetics
Understanding the mathematical divergence between linear first-order and capacity-limited zero-order kinetics is paramount for safe pharmacotherapy and licensing examination success. First-Order Kinetics: Zero-Order Kinetics:
- [Plasma Concentration] [Plasma Concentration]
- │ ╲ │ ╲
- │ ╲ (Exponential) │ ╲ (Linear Constant Drop)
- │ ╲ │ ╲
- │ '--.. │ ╲
- └────────────── └───────
- Time Time
- Rate = - ke * C Rate = - k0
- (Constant Fraction per Hour) (Constant Milligrams per Hour)
- 1. First-Order (Linear) Kinetics
Mechanism : Eliminating enzymes and transporters operate at concentrations far below their saturation threshold ( C p ≪ K m C_p \ll K_m C p ≪ K m ).
Rate of Elimination : Directly proportional to drug concentration: d C d t = − k e C \frac{dC}{dt} = -k_e C d t d C = − k e C .
Fraction Eliminated : A constant fraction (percentage) of drug is cleared per unit time.
Parameters : C L CL C L , V d V_d V d , k e k_e k e , and t 1 / 2 t_{1/2} t 1/2 remain constant regardless of the administered dose.
Dose Proportionality : Doubling the maintenance dose exactly doubles the steady-state concentration ( C ss C_{\text{ss}} C ss ).
2. Zero-Order (Non-Linear / Saturation) Kinetics
Mechanism : Metabolic enzymes or active transport mechanisms are fully saturated at standard therapeutic concentrations ( C p ≫ K m C_p \gg K_m C p ≫ K m ).
Rate of Elimination : Fixed and independent of drug concentration: d C d t = − k 0 \frac{dC}{dt} = -k_0 d t d C = − k 0 .
Amount Eliminated : A constant absolute amount (e.g., milligrams per hour) is eliminated per unit time.
Parameters : Clearance and half-life are not constant; clearance declines and half-life prolongs as the concentration rises.
Dose Proportionality : A small increase in dose produces a disproportionate, dramatic surge in serum concentration and toxicity.
Michaelis-Menten Kinetics: The Bridge
Many non-linear drugs follow Michaelis-Menten kinetics , described by the enzyme kinetics equation:
− d C d t = V max × C K m + C -\frac{dC}{dt} = \frac{V_{\text{max}} \times C}{K_m + C} − d t d C = K m + C V max × C
Where V max V_{\text{max}} V max is the maximum rate of metabolism (capacity) and K m K_m K m is the Michaelis constant (the drug concentration at which the rate of metabolism reaches half of V max V_{\text{max}} V max ).
Clinical Characteristic First-Order Elimination Michaelis-Menten (Capacity-Limited) Kinetics
Elimination Rate Proportional to concentration (constant % per hour) Saturable; transitions from linear to fixed mg/hr at higher levels
- Clearance ( C L CL C L ) Constant across all therapeutic doses Decreases as serum concentration increases
- Half-life ( t 1 / 2 t_{1/2} t 1/2 ) Constant Prolongs progressively with increasing concentration
Dose Adjustments Predictable: D 1 C 1 = D 2 C 2 \frac{D_1}{C_1} = \frac{D_2}{C_2} C 1 D 1 = C 2 D 2 Unpredictable: small dose steps yield massive concentration spikes
Classic Examples Most therapeutic drugs (Vancomycin, Aminoglycosides, Cephalosporins) Phenytoin , Ethanol , High-dose Salicylates (Aspirin)
Caution
Phenytoin Clinical Pitfall : The typical human K m K_m K m for phenytoin is 4 to 6 mg/L 4\text{ to }6\text{ mg/L} 4 to 6 mg/L ( 16 – 24 μ mol/L 16\text{--}24\ \mu\text{mol/L} 16 – 24 μ mol/L ). Because the therapeutic target range for total phenytoin is 10 to 20 mg/L 10\text{ to }20\text{ mg/L} 10 to 20 mg/L ( 40 – 80 μ mol/L 40\text{--}80\ \mu\text{mol/L} 40 – 80 μ mol/L ), hepatic CYP2C9 and CYP2C19 enzymes are near saturation across the entire therapeutic range. An incremental dose increase as small as 25 – 50 mg/day 25\text{--}50\text{ mg/day} 25 – 50 mg/day can double or triple serum concentrations, precipitating severe neurotoxicity (ataxia, nystagmus, altered mental status).
Steady-State Kinetics ( C ss C_{\text{ss}} C ss ) and Dosing Regimens
When a drug is administered repeatedly at regular intervals (or via continuous IV infusion), drug accumulates until the rate of drug administration (Input) equals the rate of drug elimination (Output) . This equilibrium state is termed steady state ( C ss C_{\text{ss}} C ss ) .
The Rule of 4 to 5 4\text{ to }5 4 to 5 Half-Lives
Under first-order kinetics, the time required to reach steady state depends exclusively on the elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) of the drug, regardless of the dosing frequency, infusion rate, or dose size:
- After 1 × t 1 / 2 1 \times t_{1/2} 1 × t 1/2 : 50.0 % 50.0\% 50.0% of steady state is attained
- After 2 × t 1 / 2 2 \times t_{1/2} 2 × t 1/2 : 75.0 % 75.0\% 75.0% of steady state is attained
- After 3 × t 1 / 2 3 \times t_{1/2} 3 × t 1/2 : 87.5 % 87.5\% 87.5% of steady state is attained
After 4 × t 1 / 2 4 \times t_{1/2} 4 × t 1/2 : 93.75 % 93.75\% 93.75% of steady state is attained (clinical steady state)
After 5 × t 1 / 2 5 \times t_{1/2} 5 × t 1/2 : 96.88 % 96.88\% 96.88% of steady state is attained (practical equilibrium)
Conversely, when drug administration is permanently discontinued, the time required for complete drug washout is also 4 to 5 4\text{ to }5 4 to 5 elimination half-lives ( < 3.12 % < 3.12\% < 3.12% remaining).
Note
Increasing the continuous IV infusion rate from 2 mg/min 2\text{ mg/min} 2 mg/min to 4 mg/min 4\text{ mg/min} 4 mg/min will double the ultimate steady-state concentration ( C ss C_{\text{ss}} C ss ), but will not shorten the time needed to reach that new steady state . The patient will still require 4 to 5 4\text{ to }5 4 to 5 half-lives to reach the higher plateau.
Average Steady-State Concentration ( C ss,avg C_{\text{ss,avg}} C ss,avg )
For intermittent oral or IV dosing at interval τ \tau τ :
C ss,avg = F × Dose C L × τ = F × Dose k e × V d × τ C_{\text{ss,avg}} = \frac{F \times \text{Dose}}{CL \times \tau} = \frac{F \times \text{Dose}}{k_e \times V_d \times \tau} C ss,avg = C L × τ F × Dose = k e × V d × τ F × Dose
Where τ \tau τ is the dosing interval in hours. For a continuous IV infusion ( F = 1.0 F = 1.0 F = 1.0 , Dose τ = R 0 \frac{\text{Dose}}{\tau} = R_0 τ Dose = R 0 , the zero-order infusion rate):
- C ss = R 0 C L C_{\text{ss}} = \frac{R_0}{CL} C ss = C L R 0
- Peak and Trough Oscillations at Steady State
For intermittent intravenous boluses or rapid-release oral doses:
C max,ss = Dose / V d 1 − e − k e τ C_{\text{max,ss}} = \frac{\text{Dose} / V_d}{1 - e^{-k_e \tau}} C max,ss = 1 − e − k e τ Dose / V d C min,ss = C max,ss × e − k e τ = ( Dose / V d ) × e − k e τ 1 − e − k e τ C_{\text{min,ss}} = C_{\text{max,ss}} \times e^{-k_e \tau} = \frac{(\text{Dose} / V_d) \times e^{-k_e \tau}}{1 - e^{-k_e \tau}} C min,ss = C max,ss × e − k e τ = 1 − e − k e τ ( Dose / V d ) × e − k e τ
The term 1 1 − e − k e τ \frac{1}{1 - e^{-k_e \tau}} 1 − e − k e τ 1 is the accumulation factor ( R R R ) , which quantifies how much higher the steady-state peak is compared to the first dose peak.
- Regimen Design: Loading Dose ( L D LD L D ) vs. Maintenance Dose ( M D MD M D )
- 1. Loading Dose ( L D LD L D )
A loading dose is an initial larger dose administered at the onset of therapy to rapidly achieve target therapeutic concentrations without waiting 4 to 5 4\text{ to }5 4 to 5 half-lives. This is essential in life-threatening conditions (e.g., status epilepticus, severe septic shock, acute ventricular arrhythmias):
L D = V d × C target F LD = \frac{V_d \times C_{\text{target}}}{F} L D = F V d × C target
When a salt form is used (e.g., aminophylline contains 80 % 80\% 80% active theophylline, so S = 0.8 S = 0.8 S = 0.8 ):
L D = V d × C target S × F LD = \frac{V_d \times C_{\text{target}}}{S \times F} L D = S × F V d × C target
Important
Notice that clearance ( C L CL C L ) and half-life ( t 1 / 2 t_{1/2} t 1/2 ) do not appear in the loading dose equation . A patient with total anuric renal failure requires the exact same weight-adjusted loading dose of vancomycin or aminoglycoside as a patient with normal renal function, because L D LD L D depends solely on the volume of distribution ( V d V_d V d ) into which the initial dose must distribute.
2. Maintenance Dose ( M D MD M D )
A maintenance dose is administered repeatedly to replenish the exact quantity of drug lost to systemic clearance over the dosing interval τ \tau τ , preserving the target steady-state concentration:
Rate of Input = Rate of Output \text{Rate of Input} = \text{Rate of Output} Rate of Input = Rate of Output F × M D τ = C L × C target \frac{F \times MD}{\tau} = CL \times C_{\text{target}} τ F × M D = C L × C target M D = C L × C target × τ F MD = \frac{CL \times C_{\text{target}} \times \tau}{F} M D = F C L × C target × τ
If using a salt active fraction ( S S S ):
M D = C L × C target × τ S × F MD = \frac{CL \times C_{\text{target}} \times \tau}{S \times F} M D = S × F C L × C target × τ
Unlike the loading dose, the maintenance dose is strictly dependent on clearance ( C L CL C L ) . When renal or hepatic clearance declines, the maintenance dose must be proportionally reduced (either by decreasing the dose size or extending the dosing interval τ \tau τ ).
- Step-by-Step Worked Clinical Scenarios
- Scenario 1: Calculating an Emergency IV Loading Dose
Clinical Case : A 70 kg 70\text{ kg} 70 kg adult with atrial fibrillation and a rapid ventricular rate, who has heart failure with reduced ejection fraction and normal renal function, needs digoxin loading. The target serum concentration ( C target C_{\text{target}} C target ) is 1.0 μ g/L 1.0\ \mu\text{g/L} 1.0 μ g/L . Digoxin's volume of distribution ( V d V_d V d ) is about 7 L/kg 7\text{ L/kg} 7 L/kg , and IV bioavailability is F = 1.0 F = 1.0 F = 1.0 .
Calculate the Total Volume of Distribution : V d = 7 L/kg × 70 kg = 490 L V_d = 7\text{ L/kg} \times 70\text{ kg} = 490\text{ L} V d = 7 L/kg × 70 kg = 490 L
Apply the Loading Dose Equation : L D IV = V d × C target F = 490 L × 1.0 μ g/L 1.0 = 490 μ g ≈ 0.5 mg LD_{\text{IV}} = \frac{V_d \times C_{\text{target}}}{F} = \frac{490\text{ L} \times 1.0\ \mu\text{g/L}}{1.0} = 490\ \mu\text{g} \approx 0.5\text{ mg} L D IV = F V d × C target = 1.0 490 L × 1.0 μ g/L = 490 μ g ≈ 0.5 mg
Clinical Recommendation : Give the IV load in divided doses: about half first, then the rest in two portions roughly 6 hours apart, checking heart rate, potassium and renal function before each portion. An oral load with tablets ( F ≈ 0.7 F \approx 0.7 F ≈ 0.7 ) is larger: 490 ÷ 0.7 = 700 μ g 490 \div 0.7 = 700\ \mu\text{g} 490 ÷ 0.7 = 700 μ g . Because digoxin's V d V_d V d is so large, the load depends on body size and not on renal function. Renal impairment lowers the maintenance dose, not the loading dose.
Scenario 2: Calculating an Oral Maintenance Dose
Clinical Case : A 60 kg 60\text{ kg} 60 kg patient with chronic asthma requires oral theophylline. The desired target average steady-state concentration is 12 mg/L 12\text{ mg/L} 12 mg/L . Pharmacokinetic population parameters show theophylline clearance C L = 0.04 L/kg/hr CL = 0.04\text{ L/kg/hr} C L = 0.04 L/kg/hr , oral bioavailability F = 1.0 F = 1.0 F = 1.0 , and the prescribed dosing interval is every 12 hours ( τ = 12 hr \tau = 12\text{ hr} τ = 12 hr ).
Calculate Systemic Clearance : C L = 0.04 L/kg/hr × 60 kg = 2.4 L/hr CL = 0.04\text{ L/kg/hr} \times 60\text{ kg} = 2.4\text{ L/hr} C L = 0.04 L/kg/hr × 60 kg = 2.4 L/hr
Calculate Required Maintenance Dose per 12-Hour Interval : M D = C L × C target × τ F = 2.4 L/hr × 12 mg/L × 12 hr 1.0 = 345.6 mg MD = \frac{CL \times C_{\text{target}} \times \tau}{F} = \frac{2.4\text{ L/hr} \times 12\text{ mg/L} \times 12\text{ hr}}{1.0} = 345.6\text{ mg} M D = F C L × C target × τ = 1.0 2.4 L/hr × 12 mg/L × 12 hr = 345.6 mg
Practical Formulation Selection : Round to a dose the available extended-release product can deliver, erring low because theophylline has a narrow therapeutic range (for example, 300 mg 300\text{ mg} 300 mg every 12 hours). Then adjust using serum concentrations once steady state is reached.